JP2005535676A - 腫瘍の処置における放射免疫療法の効果の増強 - Google Patents

腫瘍の処置における放射免疫療法の効果の増強 Download PDF

Info

Publication number
JP2005535676A
JP2005535676A JP2004522646A JP2004522646A JP2005535676A JP 2005535676 A JP2005535676 A JP 2005535676A JP 2004522646 A JP2004522646 A JP 2004522646A JP 2004522646 A JP2004522646 A JP 2004522646A JP 2005535676 A JP2005535676 A JP 2005535676A
Authority
JP
Japan
Prior art keywords
tumor
radioimmunotherapy
methyl
combination
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004522646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535676A5 (https=
Inventor
ヤニナ・バラノフスカ−コルティレヴィッチ
貴 栗崎
道雄 阿部
アーネ・オストマン
クリスティアン・ピエトラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of JP2005535676A publication Critical patent/JP2005535676A/ja
Publication of JP2005535676A5 publication Critical patent/JP2005535676A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004522646A 2002-07-19 2003-07-17 腫瘍の処置における放射免疫療法の効果の増強 Pending JP2005535676A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39734702P 2002-07-19 2002-07-19
PCT/IB2003/003257 WO2004009089A1 (en) 2002-07-19 2003-07-17 Enhancing the effect of radioimmunotherapy in the treatment of tumors

Publications (2)

Publication Number Publication Date
JP2005535676A true JP2005535676A (ja) 2005-11-24
JP2005535676A5 JP2005535676A5 (https=) 2006-09-07

Family

ID=30771040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004522646A Pending JP2005535676A (ja) 2002-07-19 2003-07-17 腫瘍の処置における放射免疫療法の効果の増強

Country Status (6)

Country Link
US (1) US20070037825A1 (https=)
EP (1) EP1530474A1 (https=)
JP (1) JP2005535676A (https=)
AU (1) AU2003247094A1 (https=)
CA (1) CA2492878A1 (https=)
WO (1) WO2004009089A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
ATE437657T1 (de) * 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040229A2 (en) * 1999-01-06 2000-07-13 Maxim Pharmaceuticals, Inc. Synergistic tumorcidal response induced by histamine
JP2001002586A (ja) * 1999-06-21 2001-01-09 Toagosei Co Ltd 重粒子線療法用薬剤
WO2001024684A2 (en) * 1999-10-07 2001-04-12 Aguilar Cordova Carlos Estuard Methods for treatment of solid tumors and metastasis by gene therapy
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用
WO2000040229A2 (en) * 1999-01-06 2000-07-13 Maxim Pharmaceuticals, Inc. Synergistic tumorcidal response induced by histamine
JP2001002586A (ja) * 1999-06-21 2001-01-09 Toagosei Co Ltd 重粒子線療法用薬剤
WO2001024684A2 (en) * 1999-10-07 2001-04-12 Aguilar Cordova Carlos Estuard Methods for treatment of solid tumors and metastasis by gene therapy

Also Published As

Publication number Publication date
EP1530474A1 (en) 2005-05-18
AU2003247094A1 (en) 2004-02-09
AU2003247094A8 (en) 2004-02-09
CA2492878A1 (en) 2004-01-29
US20070037825A1 (en) 2007-02-15
WO2004009089A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
JP7650938B2 (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
Paganelli et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin
Riva et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2
JP6734350B2 (ja) 有利な特性を有する放射性医薬溶液
BR112016011025B1 (pt) Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico
JP2024523344A (ja) 生物製剤を複数のキレーターと組み合わせるための方法及び材料
Behr et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type
BR112020018560A2 (pt) Agentes de ligação bi específicos e usos dos mesmos
Hajjar et al. Phase I radioimmunotherapy trial with iodine-131—labeled humanized MN-14 anti—carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer
JPH0684315B2 (ja) ヒト腫瘍治療用注射組成物
Pougoue Ketchemen et al. Effectiveness of [67Cu] Cu-trastuzumab as a theranostic against HER2-positive breast cancer
Zacchetti et al. 177Lu-labeled MOv18 as compared to 131I-or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts
TW202440171A (zh) 治療前列腺癌之方法
JP2005532343A (ja) 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物
JP2005535676A (ja) 腫瘍の処置における放射免疫療法の効果の増強
IL322112A (en) Methods for treating glioblastoma
IL322257A (en) Methods of treating breast cancer
JP2025503096A (ja) がんの処置および撮像のための複合体
JP3794517B2 (ja) 腫瘍診断剤
Maraveyas et al. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma
JP2005535676A5 (https=)
JP2022524696A (ja) 甲状腺髄様がん標的用組成物
RU2795398C2 (ru) Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория
CN121866076A (zh) 新型治疗靶标
WO2025126151A1 (en) Methods for treating breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706